CCS
BIO icon

Concentric Capital Strategies’s Bio-Rad Laboratories Class A BIO Stock Holding History

Concentric Capital Strategies’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96M Buy
+23,692
New +$6.72M 0.39% 46
2023
Q1 		– Sell
-2,960
Closed -$1.24M – 133
2022
Q4 		$1.24M Sell
2,960
-763
-20% -$308K 0.57% 78
2022
Q3 		$1.55M Buy
3,723
+2,123
+133% +$1.06M 0.55% 70
2022
Q2 		$792K Sell
1,600
-1,800
-53% -$937K 0.6% 64
2022
Q1 		$1.92M Buy
+3,400
New +$2.05M 0.62% 72

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Concentric Capital Strategies's BIO Position: Q2 2026 in Review

Concentric Capital Strategies opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 23,692 shares worth $6.96M. The stake represents 0.39% of the portfolio and ranks #46 among its holdings. This is a return to the name: Concentric Capital Strategies previously reported a position in BIO as recently as Q4 2022.

Concentric Capital Strategies first reported a position in BIO in Q1 2022 and has held it in 5 quarters since. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Concentric Capital Strategies held 23,692 shares of Bio-Rad Laboratories Class A worth $6.96M as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Concentric Capital Strategies position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.39% of Concentric Capital Strategies's portfolio in Q2 2026, its #46 holding.
  • Concentric Capital Strategies first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and has held it in 5 quarters since.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Concentric Capital Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.